EQT to acquire majority interest in Aldevron – the leading global supplier of plasmid DNA used in cell and gene therapies

EQT to partner with founder and CEO Michael Chambers, as well as TA Associates, to support Aldevron on its future growth journey EQT will support Aldevron through investments in additional production capacity, R&D, and growth initiatives and by leveraging EQT’s strong healthcare expertise, global...

EQT and CPPIB to acquire a majority equity stake in Waystar in transaction valued at $2.7 billion

EQT and CPPIB to acquire a majority stake in Waystar, a provider of critical Revenue Cycle Management software for healthcare systems and providers Bain Capital to retain a minority interest EQT, CPPIB and Bain Capital to support Waystar’s continued growth by leveraging their deep healthcare and...

Un consortium dirigé par EQT et ADIA entre en négociations exclusives pour acquérir la société de soins de la peau Nestlé Skin Health

EQT et une filiale de l’Abu Dhabi Investment Authority (« ADIA ») ont formé un partenariat avec une filiale de l'Office d'investissement des régimes de pensions du secteur public (« PSP Investments ») et d'autres investisseurs institutionnels de renom Le consortium a entamé des négociations...

Consortium led by EQT and ADIA enters exclusive negotiations to acquire skincare company Nestlé Skin Health

EQT and a wholly owned subsidiary of the Abu Dhabi Investment Authority (“ADIA”) have partnered with a wholly owned subsidiary of the Public Sector Pension Investment Board (“PSP Investments”) and other renowned institutional investors The consortium has entered into exclusive negotiations to...

Konsortium um EQT und ADIA führt exklusive Verhandlungen über den Erwerb von Nestlé Skin Health

EQT und ein Tochterunternehmen der Abu Dhabi Investment Authority (“ADIA”) haben sich mit einer hundertprozentigen Tochtergesellschaft des Public Sector Pension Investment Boards (“PSP Investments”), der Santo Holding (Familie Strüngmann) und anderen renommierten institutionellen Investoren...

EQT acquires Dellner Couplers, a global leader in train connection systems for passenger rail

EQT to acquire Dellner Couplers, a global niche market leader in couplers, gangways and adjacent products for passenger rail rolling stock EQT will support Dellner and the management team with further investments in R&D and innovation initiatives, and accelerate global growth by leveraging EQT’s...

EQT adquiere Igenomix, líder global en salud de la mujer y servicios de genética reproductiva

EQT adquiere Igenomix, una las compañías biotecnológicas más avanzadas del mundo y líder mundial en salud de la mujer y servicios de genética reproductiva para clínicas de fecundación in vitro (FIV) Igenomix presta sus servicios diagnósticos de reproducción genética a 90.000 parejas al año EQT...

EQT acquires Igenomix, a global leader in women’s health and reproductive genetic services

EQT to acquire Igenomix, one of the world’s leading biotechnology companies and a global leader in women’s health and reproductive genetic services for IVF (In Vitro Fertilization) clinics Igenomix supports approximately 90,000 couples per year in their reproductive journey EQT will support...

Sivantos und Widex schließen Fusion erfolgreich ab: Neues Unternehmen firmiert unter WS Audiology

Kombinierter Umsatz von 1,7 Milliarden Euro und eine umfassende Vertriebsplattform in mehr als 125 Märkten machen WS Audiology zu einem der drei führenden Hörgerätehersteller weltweit Jørgen Jensen, bis dato CEO von Widex, leitet WS Audiology als CEO; Wolfgang Ollig, derzeitiger CFO von Sivantos,...

Sivantos and Widex successfully complete merger: new company to operate as WS Audiology

Global top three contender with revenues of EUR 1.7 billion and a comprehensive sales and distribution platform in more than 125 markets Jørgen Jensen, until now CEO of Widex, appointed CEO; Wolfgang Ollig, Sivantos’ current CFO, appointed CFO of WS Audiology Thomas Ebeling, Chairman of the Board...

Karo Intressenter AB owns approximately 66.5 per cent of the outstanding shares in Karo Pharma Aktiebolag after the expiry of the final acceptance period

For more information, click here. 

Karo Intressenter AB äger cirka 66,5 procent av de utestående aktierna i Karo Pharma Aktiebolag efter utgången av den slutliga acceptfristen

För mer information, klicka här. 

Karo Intressenter AB fullföljer erbjudandet till aktieägarna i Karo Pharma Aktiebolag och förlänger acceptfristen

För mer information, klicka här.

Karo Intressenter AB completes the offer to the shareholders in Karo Pharma Aktiebolag and extends the acceptance period

For more information, click here.

Karo Intressenter AB publishes supplement to offer document regarding its public cash offer to the shareholders in Karo Pharma Aktiebolag

Fore more information, click here.

Karo Intressenter AB offentliggör tillägg till erbjudandehandlingen avseende det kontanta offentliga uppköpserbjudandet till aktieägarna i Karo Pharma Aktiebolag

För mer information, klicka här.

Karo Intressenter AB höjer erbjudandevederlaget i det kontanta offentliga uppköpserbjudandet till aktieägarna i Karo Pharma Aktiebolag och förlänger acceptfristen

För mer information, klicka här.

Karo Intressenter AB increases the offer price in its public cash offer to the shareholders in Karo Pharma Aktiebolag and extends the acceptance period

Fore more information, click here.

Karo Intressenter AB förlänger acceptfristen för erbjudandet till aktieägarna i Karo Pharma Aktiebolag

För mer information, klicka här.

Karo Intressenter AB extends the acceptance period for its offer to the shareholders in Karo Pharma Aktiebolag

Fore more information, click here.